Linezolid-Induced Thrombocytopenia Is Caused by Suppression of Platelet Production via Phosphorylation of Myosin Light Chain 2

• Published in: Biological & pharmaceutical bulletin Vol. 39; no. 11; pp. 1846 - 1851
• Main Authors: Tajima, Masataka, Kato, Yoshinori, Matsumoto, Jun, Hirosawa, Iori, Suzuki, Mariko, Takashio, Yuki, Yamamoto, Mao, Nishi, Yoshifumi, Yamada, Harumi
• Format: Journal Article
• Language: English
• Published: Japan The Pharmaceutical Society of Japan 2016; Pharmaceutical Society of Japan; Japan Science and Technology Agency
• Subjects: adverse effect; Animals; Anti-Bacterial Agents - adverse effects; Antibiotic resistance; Biotechnology; Blood Platelets - drug effects; Blood Platelets - metabolism; Cardiac Myosins - metabolism; Cell Differentiation - drug effects; Cell Line; Cell Line, Tumor; Cell lines; Cell proliferation; Cell Proliferation - drug effects; Cytotoxicity; Drug resistance; Erythroleukemia; Humans; L-Lactate dehydrogenase; L-Lactate Dehydrogenase - metabolism; Lactic acid; Light levels; Linezolid; Linezolid - adverse effects; Liver; Liver diseases; Male; mechanism; Megakaryocytes; Methicillin; Myosin; myosin light chain; Myosin Light Chains - metabolism; Pathogenesis; Phosphorylation; Phosphorylation - drug effects; Platelets; Rats, Wistar; Renal function; Risk factors; Rodents; Side effects; Staphylococcus aureus; Staphylococcus infections; Thrombocytopenia; Thrombocytopenia - chemically induced; Thrombocytopenia - metabolism; Vancomycin

Linezolid (LZD) is an antimicrobial that is commonly used for treatment of vancomycin-resistant Enterococci and methicillin-resistant Staphylococcus aureus infections. However, the development of thrombocytopenia, one of the most frequent adverse side effects of this antimicrobial, can lead to disco...